What should you know about Entyvio for ulcerative colitis?

Entyvio contains vedolizumab and acts on immune-cell trafficking into the digestive tract. This can reduce inflammation in the bowel lining, helping some people with ulcerative colitis have less diarrhoea, urgency, bleeding, and abdominal pain. It is not suitable for every flare or every person, and improvement may take time. A specialist weighs disease activity, previous medicines, infection history, vaccination needs, and other health conditions before treatment.

Before each dose, tell the treatment team about fever, infection, tuberculosis exposure, liver disease, allergies, pregnancy, and any new medicine. Ask about vaccines before starting; live vaccines need specific medical advice. Attend planned doses and monitoring visits, and note stool frequency, blood, urgency, pain, energy, and weight change. A GP consultation can support general health while the IBD team manages treatment. Colorectal cancer screening is a separate preventive service and should be discussed according to your individual bowel history.

Seek urgent care for severe abdominal pain, a swollen abdomen with vomiting, heavy bleeding, fainting, confusion, or inability to keep fluids down. Contact your IBD team promptly for fever, persistent cough, new infection symptoms, breathing difficulty, or a rash after treatment. Worsening diarrhoea, bleeding, or weakness may indicate active inflammation and should be reviewed promptly.

What improvement should I expect and when will we review it? How will you monitor bowel inflammation and treatment safety? Which symptoms mean I should delay a dose or call the team?